Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Literature DB >> 27742771

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Frédéric Courtier^1,2,3, Nadine Carbuccia^1,2, Séverine Garnier^1,2, Arnaud Guille^1,2, José Adélaïde^1,2, Nathalie Cervera^1,2, Véronique Gelsi-Boyer^1,2,4,3, Marie-Joelle Mozziconacci^1,2,4, Jérôme Rey^1,5,3, Norbert Vey^1,5,3, Max Chaffanet^1,2,3, Daniel Birnbaum^1,2,3, Anne Murati^6,2,4,3.

Abstract

Entities: Disease

Mesh：

Substances：
Neoplasm Proteins

Year: 2016 PMID： 27742771 PMCID： PMC5210251 DOI： 10.3324/haematol.2016.152363

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

13 in total

1. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Authors: Mandy Brecqueville; Jérôme Rey; Raynier Devillier; Arnaud Guille; Rémi Gillet; José Adélaide; Véronique Gelsi-Boyer; Christine Arnoulet; Max Chaffanet; Marie-Joelle Mozziconacci; Norbert Vey; Daniel Birnbaum; Anne Murati
Journal: Haematologica Date: 2013-08-30 Impact factor: 9.941

2. p53 lesions in leukemic transformation.

Authors: Ashot Harutyunyan; Thorsten Klampfl; Mario Cazzola; Robert Kralovics
Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245

3. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Authors: O Abdel-Wahab; A Pardanani; J Patel; M Wadleigh; T Lasho; A Heguy; M Beran; D G Gilliland; R L Levine; A Tefferi
Journal: Leukemia Date: 2011-04-01 Impact factor: 11.528

4. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors: R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal: Blood Date: 2014-12-30 Impact factor: 22.113

5. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.

Authors: Thorsten Klampfl; Ashot Harutyunyan; Tiina Berg; Bettina Gisslinger; Martin Schalling; Klaudia Bagienski; Damla Olcaydu; Francesco Passamonti; Elisa Rumi; Daniela Pietra; Roland Jäger; Lisa Pieri; Paola Guglielmelli; Ilaria Iacobucci; Giovanni Martinelli; Mario Cazzola; Alessandro M Vannucchi; Heinz Gisslinger; Robert Kralovics
Journal: Blood Date: 2011-04-29 Impact factor: 22.113

6. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

Authors: Raajit Rampal; Jihae Ahn; Omar Abdel-Wahab; Michelle Nahas; Kai Wang; Doron Lipson; Geoff A Otto; Roman Yelensky; Todd Hricik; Anna Sophia McKenney; Gabriela Chiosis; Young Rock Chung; Suveg Pandey; Marcel R M van den Brink; Scott A Armstrong; Ahmet Dogan; Andrew Intlekofer; Taghi Manshouri; Christopher Y Park; Srdan Verstovsek; Franck Rapaport; Philip J Stephens; Vincent A Miller; Ross L Levine
Journal: Proc Natl Acad Sci U S A Date: 2014-12-02 Impact factor: 11.205

7. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors: Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal: Blood Date: 2009-12-11 Impact factor: 22.113

Review 8. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal: Blood Date: 2016-04-11 Impact factor: 22.113

9. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors: Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal: Blood Date: 2014-01-29 Impact factor: 22.113

10. Comparative genomic analysis of primary tumors and metastases in breast cancer.

Authors: François Bertucci; Pascal Finetti; Arnaud Guille; José Adélaïde; Séverine Garnier; Nadine Carbuccia; Audrey Monneur; Emmanuelle Charafe-Jauffret; Anthony Goncalves; Patrice Viens; Daniel Birnbaum; Max Chaffanet
Journal: Oncotarget Date: 2016-05-10

17 in total

1. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors: Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal: Blood Adv Date: 2018-12-26

2. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.

Authors: Vikas Gupta; James A Kennedy; Jose-Mario Capo-Chichi; Soyoung Kim; Zhen-Huan Hu; Edwin P Alyea; Uday R Popat; Ronald M Sobecks; Bart L Scott; Aaron T Gerds; Rachel B Salit; H Joachim Deeg; Ryotara Nakamura; Wael Saber
Journal: Blood Adv Date: 2020-11-10

3. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Authors: Damien Luque Paz; Rébecca Jouanneau-Courville; Jérémie Riou; Jean-Christophe Ianotto; Françoise Boyer; Aurélie Chauveau; Maxime Renard; Jean-Claude Chomel; Emilie Cayssials; Maria-Pilar Gallego-Hernanz; Cédric Pastoret; Anne Murati; Frédéric Courtier; Marie-Christine Rousselet; Isabelle Quintin-Roué; Laurane Cottin; Corentin Orvain; Sylvain Thépot; Jean-Marie Chrétien; Yves Delneste; Norbert Ifrah; Odile Blanchet; Mathilde Hunault-Berger; Eric Lippert; Valérie Ugo
Journal: Blood Adv Date: 2020-10-13

4. Oral idasanutlin in patients with polycythemia vera.

Authors: John Mascarenhas; Min Lu; Heidi Kosiorek; Elizabeth Virtgaym; Lijuan Xia; Lonette Sandy; Ruben Mesa; Bruce Petersen; Noushin Farnoud; Vesna Najfeld; Raajit Rampal; Amylou Dueck; Ronald Hoffman
Journal: Blood Date: 2019-06-05 Impact factor: 22.113